Moderate to Severe Acute Pain Market Report 2034: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | Vertex Pharmaceuticals, Satsuma Pharmaceuticals, Ocular Therapeutix, Alcon, Kala Pharmaceuticals, Amneal Pharma

The Moderate to Severe Acute Pain market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Moderate to Severe Acute Pain pipeline products will significantly revolutionize the Moderate to Severe Acute Pain market dynamics.

DelveInsight's "Moderate to Severe Acute Pain Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Moderate to Severe Acute Pain, historical and forecasted epidemiology as well as the Moderate to Severe Acute Pain market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Moderate to Severe Acute Pain market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2020 to 2034. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

To Know in detail about the Moderate to Severe Acute Pain market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Moderate to Severe Acute Pain Market Insights
https://www.delveinsight.com/sample-request/moderate-to-severe-acute-pain-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Moderate to Severe Acute Pain Market Report:
• The Moderate to Severe Acute Pain market size was valued ~USD 1,400 million in 2024 and is anticipated to grow with a significant CAGR of 13.9% during the study period (2020-2034)
• In March 2025, Tris Pharma reported positive topline results from its ALLEVIATE-2 Phase III pivotal trial assessing cebranopadol for managing moderate-to-severe acute pain after bunionectomy surgery. The company intends to file a New Drug Application (NDA) with the FDA in 2025.
• In 2024, the United States held the largest share of the moderate-to-severe acute pain market among the 7MM, generating close to USD 3,500 million. It was followed by the EU4, which is expected to witness growth throughout the forecast period (2025-2034).
• Among the anticipated emerging therapies, NURTEC ODT/VYDURA (rimegepant) is projected to lead the moderate-to-severe acute pain market across the 7MM by 2034.
• ATX101, a combination of bupivacaine and a biopolymer formulation, is anticipated to launch during the forecast period and reach a market size of USD 411 million in the 7MM by 2034. This therapy is aimed at patients experiencing moderate-to-severe post-operative acute pain.
• Topline results for QUTENZA are expected in the fourth quarter of 2025. If the findings are positive, Averitas Pharma plans to file a supplemental new drug application (sNDA) for the QUTENZA (capsaicin) 8% topical system in 2026.
• Key companies involved in developing treatments for moderate-to-severe postoperative acute pain include Arthritis Innovation/Medincell (F14), Oculis (OCS-01), PainReform (PRF-110), Cali Biosciences (CPL-01), Neumentum (NTM-001), Tris Pharma (cebranopadol/TRN-228), Viatris (meloxicam/MR 107A 02), Xgene Pharmaceutical (XG005), Allay Therapeutics (ATX101), Latigo Biotherapeutics (LTG-001), Halia Therapeutics (HT-6184), among others.
• In 2024, the United States recorded the highest number of acute pain incident cases among the 7MM, with approximately 86,808 reported cases.
• In 2024, the UK reported around 4,417 cases of trauma-related pain, 3,492 cases of post-operative pain, and 3,306 cases linked to acute medical illness.
• In 2024, Japan reported approximately 8,419 cases of moderate acute pain and around 2,078 cases of severe acute pain.
• Key Moderate to Severe Acute Pain Companies: Vertex Pharmaceuticals, Satsuma Pharmaceuticals, Ocular Therapeutix, Alcon/Kala Pharmaceuticals, Amneal Pharmaceuticals, Pfizer, Eli Lilly, and others
• Key Moderate to Severe Acute Pain Therapies: JOURNAVX, ATZUMI (dihydroergotamine), DEXTENZA (dexamethasone), INVELTYS (loteprednol etabonate ophthalmic suspension), BREKIYA (dihydroergotamine mesylate), ZAVZPRET (zavegepant), EMGALITY (galcanezumab-gnlm), and others
• The Moderate to Severe Acute Pain epidemiology based on gender analyzed that, it can be concluded that there is no significant difference in occurrence of Moderate to Severe Acute Pain among male and female population

Get a Free sample for the Moderate to Severe Acute Pain Market Report:
https://www.delveinsight.com/report-store/moderate-to-severe-acute-pain-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Moderate to Severe Acute Pain Market
The dynamics of the Moderate to Severe Acute Pain market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2020-2034.
"Of the emerging therapies, one of the most anticipated product to get launched is CL-108. Apart from this, several other molecules are in mid to late stage."

Moderate to Severe Acute Pain Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Moderate to Severe Acute Pain Epidemiology Segmentation:
The Moderate to Severe Acute Pain market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Moderate to Severe Acute Pain
• Prevalent Cases of Moderate to Severe Acute Pain by severity
• Gender-specific Prevalence of Moderate to Severe Acute Pain
• Diagnosed Cases of Episodic and Chronic Moderate to Severe Acute Pain

Download the report to understand which factors are driving Moderate to Severe Acute Pain epidemiology trends @ Moderate to Severe Acute Pain Epidemiological Insights
https://www.delveinsight.com/sample-request/moderate-to-severe-acute-pain-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Moderate to Severe Acute Pain Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Moderate to Severe Acute Pain market or expected to get launched during the study period. The analysis covers Moderate to Severe Acute Pain market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Moderate to Severe Acute Pain Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Moderate to Severe Acute Pain Therapies and Key Companies
• JOURNAVX: Vertex Pharmaceuticals
• ATZUMI (dihydroergotamine): Satsuma Pharmaceuticals
• DEXTENZA (dexamethasone): Ocular Therapeutix
• INVELTYS (loteprednol etabonate ophthalmic suspension): Alcon/Kala Pharmaceuticals
• BREKIYA (dihydroergotamine mesylate): Amneal Pharmaceuticals
• ZAVZPRET (zavegepant): Pfizer
• EMGALITY (galcanezumab-gnlm): Eli Lilly

To know more about Moderate to Severe Acute Pain treatment, visit @ Moderate to Severe Acute Pain Medications https://www.delveinsight.com/sample-request/moderate-to-severe-acute-pain-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Scope of the Moderate to Severe Acute Pain Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Moderate to Severe Acute Pain Companies: Vertex Pharmaceuticals, Satsuma Pharmaceuticals, Ocular Therapeutix, Alcon/Kala Pharmaceuticals, Amneal Pharmaceuticals, Pfizer, Eli Lilly, and others
• Key Moderate to Severe Acute Pain Therapies: JOURNAVX, ATZUMI (dihydroergotamine), DEXTENZA (dexamethasone), INVELTYS (loteprednol etabonate ophthalmic suspension), BREKIYA (dihydroergotamine mesylate), ZAVZPRET (zavegepant), EMGALITY (galcanezumab-gnlm), and others
• Moderate to Severe Acute Pain Therapeutic Assessment: Moderate to Severe Acute Pain current marketed and Moderate to Severe Acute Pain emerging therapies
• Moderate to Severe Acute Pain Market Dynamics: Moderate to Severe Acute Pain market drivers and Moderate to Severe Acute Pain market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Moderate to Severe Acute Pain Unmet Needs, KOL's views, Analyst's views, Moderate to Severe Acute Pain Market Access and Reimbursement

Discover more about therapies set to grab major Moderate to Severe Acute Pain market share @ Moderate to Severe Acute Pain Treatment Landscape
https://www.delveinsight.com/sample-request/moderate-to-severe-acute-pain-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Moderate to Severe Acute Pain Market Report Introduction
2. Executive Summary for Moderate to Severe Acute Pain
3. SWOT analysis of Moderate to Severe Acute Pain
4. Moderate to Severe Acute Pain Patient Share (%) Overview at a Glance
5. Moderate to Severe Acute Pain Market Overview at a Glance
6. Moderate to Severe Acute Pain Disease Background and Overview
7. Moderate to Severe Acute Pain Epidemiology and Patient Population
8. Country-Specific Patient Population of Moderate to Severe Acute Pain
9. Moderate to Severe Acute Pain Current Treatment and Medical Practices
10. Moderate to Severe Acute Pain Unmet Needs
11. Moderate to Severe Acute Pain Emerging Therapies
12. Moderate to Severe Acute Pain Market Outlook
13. Country-Wise Moderate to Severe Acute Pain Market Analysis (2020-2034)
14. Moderate to Severe Acute Pain Market Access and Reimbursement of Therapies
15. Moderate to Severe Acute Pain Market Drivers
16. Moderate to Severe Acute Pain Market Barriers
17. Moderate to Severe Acute Pain Appendix
18. Moderate to Severe Acute Pain Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Related Reports:

Moderate to Severe Acute Pain Pipeline https://www.delveinsight.com/report-store/moderate-to-severe-acute-pain-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
"Moderate to Severe Acute Pain Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Moderate to Severe Acute Pain market. A detailed picture of the Moderate to Severe Acute Pain pipeline landscape is provided, which includes the disease overview and Moderate to Severe Acute Pain treatment guidelines.

Moderate to Severe Acute Pain Epidemiology https://www.delveinsight.com/report-store/moderate-to-severe-acute-pain-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Moderate to Severe Acute Pain Epidemiology Forecast to 2034' report delivers an in-depth understanding of the disease, historical and forecasted Moderate to Severe Acute Pain epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports by DelveInsight
• Nerve Repair And Regeneration Devices- Market Insights: https://www.delveinsight.com/report-store/nerve-repair-and-regeneration-market
• Intracranial Pressure Monitoring Devices Market: https://www.delveinsight.com/report-store/intracranial-pressure-monitoring-devices-market
• Diabetic Wound Market: https://www.delveinsight.com/report-store/diabetic-foot-ulcers-dfus-market
• Sglt2 Inhibitors Market: https://www.delveinsight.com/report-store/sglt2-inhibitors-market
• Electroencephelographs Pipeline Insight: https://www.delveinsight.com/report-store/epilepsy-pipeline-insight
• Fabry Disease Market: https://www.delveinsight.com/report-store/fabry-disease-market
• Dental Implants And Prosthesis Market: https://www.delveinsight.com/report-store/dental-implants-and-prosthesis-market

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.